Search Scholars Central
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
Advanced searchHide advanced search
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Mini review · 29 Apr 2024 Mini review · 29 Apr 2024 Empowering the immune system and the role of checkpoint blockade in cancer defense.
Conference abstract · 4 Jan 2021 Translational oncology and the new generation Immunotherapy
modulations. The emerging anti-cancer therapies have immune stimulatory orientation to focus on immune checkpoint blockade and to rejuvenate T-cell mediated cancer cell death. Monoclonal antibodies targeting Cytotoxic
Editorial · 16 Jun 2020 Research of Cancer Surgery
Research of Cancer Surgery: Progress in new cancer treatments is accelerating so
Research article · 18 Nov 2019 Small Molecule Inhibitors as an Alternative to Antibody Blockade in Immunotherapy
application of immune checkpoint blockade for the treatment of cancer has revolutionized immunotherapy regimes over the past few years. This approach has seen much success using antibody blockade of programmed
Conference abstract · 28 Jul 2016 Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T-cell signaling switch and emerging target in cancer immunotherapy
tumors in cancer patients has been a goal for many decades. Very recently, blockade of immune checkpoints CTLA-4 and PD-1 has emerged as promising cancer immune therapies. Even
Conference abstract · 15 Sep 2018 Monitoring immune response in tumors
microbiome may shape anti-tumor immune responses as well as responses to immune checkpoint blockade and other immunotherapies. Tumor-microenvironment interactions require longitudinal assessment throughout the course of…
Conference abstract · 23 Jul 2018 Monitoring immune response in tumors
microbiome may shape anti-tumor immune responses as well as responses to immune checkpoint blockade and other immunotherapies. Tumor-microenvironment interactions require longitudinal assessment throughout the course of…
Conference abstract PD-1 and Tim-3 blocking dose not improve the apoptosis of leukemic cells by peripheral blood CD8+ T cells in chronic lymphocytic leukemia
last decade, immunotherapy strategy based on the immune checkpoint inhibitors has achieved invaluable success in tumor therapy. In this in vitro study, the effect ... vitro and in vivo studies are needed to more address…
Mini review · 31 Aug 2022 Research on Anti-Cancer Therapies
Despite immune checkpoint blockade's unnoticed effectiveness in providing certain non-small-cell lung cancer NSCLC patients with long-lasting responses, the majority of patients do not react. There ... increase the…
Perspective · 22 Mar 2022 Tumor Treatment and Prevention with Cancer vaccines
prospective treatment techniques for eradicating tumours by triggering antitumor immunity in the patient. Immune checkpoint blockade (ICB) therapies and chimeric antigen receptor (CAR)-engineered T-cell immunotherapies…
Commentary · 10 Oct 2025 Unveiling ST2 as a Novel Immune Checkpoint in AML
While anti-PD1/PDL1 immune checkpoint blockade has shown promising clinical success in solid tumors [1,2] its effectiveness in Acute Myeloid Leukemia (AML) remains limited, AML is considered ... therapies and supportive…
Review article · 2017 Melanoma Metamorphoses: Advances in Biology and Therapy
blockers also yields long-term responses, but there remains many patients unresponsive to immune checkpoint blockade or whom develop resistance. Host and tumor-specific resistance mechanisms are explored. Some…
Research article · 8 Sep 2021 Radiomics Approaches to Assess Tumours Anti-PD-1 or Anti-PD-L1 Immunotherapy: Imaging Biomarkers, New Development and Challenges
this new treatment. Thus, identifying predictive biomarkers to select patients who benefit from immune checkpoint blockades therapy is crucial. Computational medical imaging (called as radiomics), which is a rapidly…
Conference abstract · 2018 Magnetite-filled micelles as a versatile delivery vehicle for a TLR4 mediated cancer nanovaccine
significantly improve the prophylicatic vaccine efficacy. Moreover, when administered in combination with an immune checkpoint blockade strategy for the immunosuppressive programmed death-ligand 1 PD-L1, the anticancer…
Conference abstract · 2 Nov 2015 Dendritic cell-based cancer immunotherapy
after hematopoietic stem cell transplantation to control minimum residual disease. In future, the blockade of immune checkpoints in combination with DC-vaccination would be promising therapeutic strategies to activate…
Conference abstract · 24 Oct 2016 T cell Bim is a novel predictive and monitoring biomarker for response to anti-PD-1 cancer therapy
circulation contributes to global immunosuppression and indirectly affects the efficiency of anti-PD-1 blockade. Since we co-discovered B7-H1 (PD-L1) in 1998 by Dr. Dong, mentor ... anti-PD-1 therapy and also identify…
Book review · 30 Dec 2024 Tumor Mutational Burden (TMB) as a Biomarker for Immunotherapy in Cancer
researchers can better identify patients who are most likely to benefit from immune checkpoint blockade therapies, thereby enhancing personalized cancer treatment strategies
Research article · 18 Sep 2024 BIRC5 Expression Correlated with Immunosuppressive Phenotype and Predicted Inferior Response to Immunotherapy in Lung Adenocarcinoma
LUAD samples, 59 normal lung samples and 54 patients who were treated with Immune Checkpoint Blockades (ICB) for Non-Small Cell Lung Cancer (NSCLC). To determine the correlation between BIRC5
Mini review · 31 Mar 2024 Immune Checkpoints in Cancer: Harnessing the Power of Immunity for Therapeutic Benefit
harness their power. We discuss the clinical success, challenges, and future perspectives of immune checkpoint blockade in cancer therapy
Mini review · 28 Jun 2022 Cancer Macrophages are Present in Endometrial Cancers: A Mini Review
macrophage differentiation, blocking immunological checkpoints, reducing monocyte recruitment to the tumour, and preventing immune checkpoint blockade
Review article · 5 Feb 2022 Evalution of Anti-inflammatory & Immunosuppressant Activity of Dexamethasone
first-line agents to combat immune-related adverse events (irAEs) that arise with immune checkpoint blockade treatment. However, it is not known if or when corticosteroids can be administered without
Commentary · 2018 Immune Checkpoints of CD8+ T Cells in Acute Myeloid Leukemia
data and other groups, and this might indicate the application of immune checkpoints blockade alone or in combination in AML treatment
Review article · 2017 Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker Based Approaches
mapping infiltration of lymphocytes, and harnessing fully humanized platforms that reconstruct and interrogate immune checkpoint blockade, ex-vivo. Summary: While cancer immunotherapy is now leading to durable outcomes…
Conference abstract · 3 Oct 2016 Update on triple negative breast cancer
also plays a critical role in TNBC. Furthermore, targeting host immune system using immune checkpoint blockade agents have been recently shown to have promising durable responses in several patients with

